CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain

  • ID: 2585935
  • Report
  • Region: Spain
  • 265 pages
  • GlobalData
1 of 6
Spain’s Pharmaceutical Market Declining While Medical Devices Sector Grows by 2020

FEATURED COMPANIES

  • Baxter
  • GSK
  • Johnson & Johnson
  • Paul Hartmann
  • MORE
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain

Summary

Spain apart from having good healthcare infrastructure and undergoing regular modernization to incorporate the latest technological advances also provides free healthcare for all citizens. Spain also has a strong network of healthcare facilities, with primary healthcare centers located within 15 minutes of any place of residence. The ratio of healthcare personnel to population is also good, with 5.3 doctors per 1,000 population in 2016.

Spanish pharmaceutical market grew to US$23.7 Billion in 2016 at a CAGR of 1% from 2014, due to the introduction of tax incentives for R&D spending. In 2015, the pharmaceutical industry invested €953m (US$1.2 billion) in R&D. This accounted for 20.9% of all private R&D spending in Spain (Invest in Spain, 2016). Spain spent approximately US$1.2 Billion on R&D, and exported approximately US$11.5 Billion of pharmaceuticals.

In 2011 and 2012, new pricing policies were implemented forcing manufacturers to sell their products below the reference price. The reference prices for pharmaceutical products in Spain are based on the indication, rather than the active molecule. Additionally, the government’s policy for the promotion of generics mandates that pharmacists should dispense the cheapest available drugs.

The market in Spain is expected to reach US$25.1 billion in 2021, registering a CAGR of 0.9% between 2017 and 2021. The driving factors for the growth of the market are the consolidation of the biotechnology sector, government support, excellent infrastructure for innovation, a highly qualified workforce and a favorable cost benefit ratio of human capita.

The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain" is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Spain.

In particular, this report provides the following analysis -
- Provides an overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
- Provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets.
- It identifies the key trends in the country’s healthcare market, and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure.
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure.

Companies mentioned in this report: Pfizer, Novartis, Sanofi, GSK and Merck & Co,GSK,Baxter International, Johnson & Johnson, Svenska Cellulosa Aktiebolaget and Paul Hartmann.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Spain, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Novartis, Sanofi, GSK and Merck & Co., as well as profiles and SWOT analyses of the major players in the medical device market: GSK,Baxter International, Johnson & Johnson, Svenska Cellulosa Aktiebolaget and Paul Hartmann
- Insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the Spanish healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect the Spanish healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnerships
- Identify, understand, and capitalize on the opportunities and challenges in the Spanish healthcare market
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Baxter
  • GSK
  • Johnson & Johnson
  • Paul Hartmann
  • MORE
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
3 Introduction
3.1 Report Guidance
4 Overview of Pharmaceutical and Medical Device Markets
4.1 Pharmaceutical Market
4.1.1 Market Overview
4.1.2 Pharmaceutical Exports and Imports
4.1.3 Supply Channels
4.1.4 Market Segments
4.1.5 Major Therapeutic Areas
4.1.6 Major Players
4.2 Medical Device Market
4.2.1 Market Overview
4.2.2 Overview of Top Five Segments
4.2.3 Diagnostic Market
4.2.4 Major Players
4.3 Market Drivers and Barriers
4.3.1 Drivers
4.3.2 Barriers
5 Market Access
5.1 Reimbursement and Payer Landscape
5.1.1 Overview of Healthcare System
5.1.2 Reimbursement Process
5.1.3 Overview of Insurance Providers
5.1.4 Patient Share in Healthcare Expenditure
5.1.5 Price Trends in the Healthcare Sector
5.1.6 Pricing Policies
5.2 Regulatory Landscape
5.2.1 Overview of Regulatory Agencies
5.2.2 Market Authorization Procedure for Pharmaceutical Products
5.2.3 New Medical Device Approval Process
5.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing
5.2.5 Licensing Process for Pharmaceutical Exports and Imports
5.2.6 Intellectual Property Rights
5.2.7 Clinical Trial Regulations
5.2.8 Pharmaceutical Advertising Regulations
5.2.9 Pharmacy Regulations
5.2.10 Labeling and Packaging Regulations
6 Country Analysis
6.1 Political Environment
6.1.1 Political Structure
6.1.2 Current Political Environment
6.1.3 Healthcare Policy Initiatives
6.2 Economic Landscape
6.3 Economic Indicators
6.3.1 Gross Domestic Product
6.3.2 Gross National Income
6.3.3 Inflation
6.3.4 Currency Exchange Rate
6.3.5 Foreign Direct Investment
6.3.6 Foreign Exchange Reserves
6.3.7 Trade Balance
6.3.8 Government Structural Balance
6.3.9 Government Net Debt
6.3.10 Major Industries
6.4 Demographics
6.4.1 Population
6.4.2 Education and Literacy
6.4.3 Employment
6.4.4 Disease Burden
6.5 Healthcare Infrastructure
6.5.1 Healthcare Facilities
6.5.2 Healthcare Parameters
6.5.3 Environmental Health
6.5.4 Healthcare Personnel
6.6 Healthcare Expenditure
6.6.1 Overview
6.6.2 Share of Public and Private Sectors
6.6.3 Major Components of Healthcare Expenditure
6.6.4 Spending in R&D
6.7 Trade Associations
6.7.1 Farmaindustria
6.7.2 The Spanish Society of Public Health and Health Services Administration
6.7.3 The Spanish Society of Health Informatics
6.7.4 Spanish Generic Medicines Association
6.8 Trade Fairs
7 Opportunities and Challenges
7.1 Opportunities
7.2 Challenges
8 Appendix
8.1 Abbreviations
8.2 Bibliography
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasts
8.3.4 Expert Panel
8.4 Contact Us
8.5 Disclaimer

1.1 List of Tables
Table 1: Pharmaceutical Market, Spain, Revenue ($bn), 2009-2016
Table 2: Pharmaceutical Market, Spain, Revenue ($bn), 2017-2021
Table 3: Pharmaceutical Market, Spain, Exports and Imports ($bn), 2009-2016
Table 4: Pharmaceutical Market, Spain, Generic Pharmaceutical Market Share (%), 2009-2016
Table 8: Pharmaceutical Market, Spain, Red Biotechnology, Share of Diagnostics Pipeline by Disease Area (%), 2016
Table 8: Pharmaceutical Market, Spain, Red Biotechnology, Share of Therapeutics Pipeline by Disease Area (%), 2016
Table 7: Pharmaceutical Market, Spain, OTC Drug Market Revenue ($bn), 2009-2016
Table 8: Pharmaceutical Market, Spain, Major OTC Drug Classes, Revenue ($bn) and Market Share (%), 2015
Table 9: Pharmaceutical Market, Spain, Major Therapeutic Areas by Units Sold (millions) and Share (%), 2015
Table 10: Pharmaceutical Market, Pfizer, Late-Stage Pipeline, 2016
Table 11: Major Products, Novartis, Global, 2016
Table 12: Late-Stage Pipeline, Novartis, Global, 2015
Table 13: Major Products, Sanofi, Global, 2015
Table 14: Late-Stage Pipeline, Sanofi, Global, 2015
Table 15: Pharmaceutical Market, Merck & Co., Global, Major Products, 2015
Table 16: Pharmaceutical Market, Merck & Co., Global, Late-Stage Pipeline, 2016
Table 17: Medical Device Market, Spain, Revenue ($bn), 2009-2016
Table 18: Medical Device Market, Spain, Revenue ($bn), 2017-2021
Table 19: Medical Device Market, Spain, Revenue ($m) and Market Share (%) by Segment, 2016
Table 20: In Vitro Diagnostics Market, Spain, Revenue ($m), 2009-2016
Table 21: In Vitro Diagnostics, Spain, Revenue ($m) and Market Share (%) of Major Players, 2014
Table 22: Diabetes Care Device Market, Spain, Revenue ($m), 2009-2016
Table 23: Diabetes Care Devices, Spain, Revenue ($m) and Market Share (%) of Major Players, 2015
Table 24: Ophthalmic Device Market, Spain, Revenue ($m), 2009-2016
Table 25: Ophthalmic Devices, Spain, Revenue ($m) and Market Share (%) of Major Players, 2015
Table 26: Orthopedic Devices, Spain, Revenue ($m), 2009-2016
Table 27: Orthopedic Devices, Spain, Revenue ($m) and Market Share (%) of Major Players, 2016
Table 28: Hospital Supplies Market, Spain, Revenue ($m), 2009-2016
Table 29: Hospital Supplies Market, Spain, Revenue ($m) and Market Share (%) of Major Players, 2014
Table 30: Medical Device Market, Spain, Diagnostic Market, Revenue ($bn), 2009-2016
Table 31: Medical Device Market, Spain, Revenue ($bn), 2017-2021
Table 32: Medical Device Market, Spain, Revenue ($m) and Market Share (%) of Major Players, 2012
Table 33: Baxter International, Global, Major Products, 2016
Table 34: Paul Hartmann, Global, Major Products, 2016
Table 35: Healthcare System, Spain, Pharmaceutical Reimbursement Categories, 2014
Table 36: Healthcare Expenditure, Spain, Out-of-Pocket Expenditure as Percentage of Total Expenditure (%), 2009-2016
Table 37: Market Access, Spain, Healthcare Consumer Price Index Annual Change (%), 2009-2016
Table 38: Economic Indicators, Spain, GDP per Capita ($), 2009-2016
Table 39: Economic Indicators, Spain, GDP per Capita ($), 2017-2021
Table 40: Economic Indicators, Spain, GDP Annual Growth (%), 2009-2016
Table 41: Economic Indicators, Spain, GDP Annual Growth (%), 2017-2021
Table 42: Economic Indicators, Spain, GNI per Capita ($), 2009-2016
Table 43: Economic Indicators, Spain, Consumer Price Index, 2009-2016
Table 44: Economic Indicators, Spain, Average Consumer Price Index, 2017-2021
Table 45: Economic Indicators, Spain, Average Consumer Price Index Annual Change (%), 2009-2016
Table 46: Economic Indicators, Spain, Currency Exchange Rate (€/$), 2009-2016
Table 47: Economic Indicators, Spain, Foreign Direct Investment ($bn), 2009-2016
Table 48: Economic Indicators, Spain, Foreign Exchange Reserves ($bn), 2009-2016
Table 49: Economic Indicators, Spain, Imports of Goods and Services ($bn), 2009-2016
Table 50: Economic Indicators, Spain, Exports of Goods and Services ($bn), 2009-2016
Table 51: Economic Indicators, Spain, General Government Structural Balance ($bn), 2009-2016
Table 52: Economic Indicators, Spain, Government Net Debt as Percentage of GDP (%), 2009-2016
Table 53: Economic Indicators, Spain, Government Net Debt as Percentage of GDP (%), 2017-2021
Table 54: Economic Indicators, Spain, Major Industries by Revenue ($bn), 2014
Table 55: Demographics, Spain, Population (million), 2009-2016
Table 56: Demographics, Spain, Population (million), 2017-2021
Table 57: Demographics, Spain, Urban-Rural Population Share (%), 2009-2016
Table 58: Demographics, Spain, Urban-Rural Population Share (%), 2017-2021
Table 59: Demographics, Spain, Population Distribution by Age Group (%), 2009-2016
Table 60: Demographics, Spain, Population Distribution by Age Group (%), 2017-2021
Table 61: Demographics, Spain, Births (per 1,000 population), 2009-2016
Table 62: Demographics, Spain, Mortality (per 1,000 population), 2009-2016
Table 63: Demographics, Spain, Major Causes of Mortality (%), 2013
Table 64: Demographics, Spain, Mortality Rate of Children Under Five (per 1,000 live births), 2009-2016
Table 65: Demographics, Spain, Immunization Rate (%), 2009-2016
Table 66: Demographics, Spain, Major Causes of Male Mortality, 2013
Table 67: Demographics, Spain, Major Causes of Female Mortality (%), 2012
Table 68: Demographics, Spain, Gender Ratio (M/F), 2009-2016
Table 69: Demographics, Spain, Life Expectancy at Birth (years), 2009-2016
Table 70: Demographics, Spain, Students Enrolled at Different Levels in Non-university Courses (%), 2014-2015
Table 71: Demographics, Spain, Students Enrolled at Different Levels in University Courses (%), 2013-2014
Table 72: Demographics, Spain, Unemployment Rate (%), 2009-2016
Table 73: Demographics, Spain, Distribution of Employment by Sector (%), 2015
Table 74: Demographics, Spain, Number of Hospital Admissions and Diseases Diagnosed, 2015
Table 75: Demographics, Spain, Major Diseases, Disability-Adjusted Life Years (000’), 2014
Table 76: Healthcare Infrastructure, Spain, Hospitals, 2009-2016
Table 77: Healthcare Infrastructure, Spain, Number of Hospitals by Type of Treatment, 2009-2016
Table 78: Healthcare Infrastructure, Spain, Number of Hospitals by Sector, 2009-2016
Table 79: Healthcare Infrastructure, Spain, Number of Hospital Beds by Sector, 2009-2016
Table 80: Healthcare Infrastructure, Spain, Hospital Beds by Type of Treatment Provided, 2009-2016
Table 81: Healthcare Infrastructure, Spain, Diagnostic Units (per 100,000 population), 2009-2016
Table 83: Healthcare Infrastructure, Spain, Hospital Beds (per 1,000 population), 2009-2016
Table 83: Healthcare Infrastructure, Spain, Doctors (per 1,000 population), 2009-2016
Table 84: Healthcare Infrastructure, Spain, PM2.5 (µg per m³), 2009-2016
Table 85: Healthcare Infrastructure, Spain, CO2 Emissions (metric tons per capita), 2009-2016
Table 86: Healthcare Infrastructure, Spain, Nurses, 2009-2016
Table 87: Healthcare Infrastructure, Spain, Pharmacists, 2009-2016
Table 88: Healthcare Infrastructure, Spain, Dentists, 2009-2016
Table 89: Healthcare Infrastructure, Spain, Qualified Midwives, 2009-2016
Table 90: Healthcare Infrastructure, Spain, Healthcare Expenditure as Percentage of GDP (%), 2009-2016
Table 91: Healthcare Infrastructure, Spain, Public-Private Share of Expenditure (%), 2009-2016
Table 92: Healthcare Infrastructure, Spain, Major Components of Healthcare Expenditure (%), 2015
Table 93: Healthcare Infrastructure, Spain, R&D Expenditure by Field (%), 2013
Table 94: Healthcare Expenditure, Spain, Major Healthcare Trade Fairs, 2017

1.2 List of Figures
Figure 1: Pharmaceutical Market, Spain, Revenue ($bn), 2009-2021
Figure 2: Medical Device Market, Spain, Revenue ($bn), 2009-2021
Figure 3: Country Profile, Spain, 2017
Figure 4: Pharmaceutical Market, Spain, Revenue ($bn), 2009-2016
Figure 5: Pharmaceutical Market, Spain, Revenue ($bn), 2017-2021
Figure 6: Pharmaceutical Market, Spain, Exports and Imports ($bn), 2009-2016
Figure 7: Pharmaceutical Market, Spain, Distribution Channels for Pharmaceuticals (%), 2012
Figure 8: Pharmaceutical Market, Spain, Generic Pharmaceutical Market Share (%), 2009-2016
Figure 9 Pharmaceutical Market, Spain, Red Biotechnology, Share of Diagnostics Pipeline by Disease Area (%), 2016
Figure 10 Pharmaceutical Market, Spain, Red Biotechnology, Share of Therapeutics Pipeline by Disease Area (%), 2016
Figure 11: Pharmaceutical Market, Spain, OTC Drug Market Revenue ($bn), 2009-2016
Figure 12: Pharmaceutical Market, Spain, Market Share of Major OTC Drug Classes (%), 2015
Figure 13: Pharmaceutical Market, Spain, Major Therapeutic Areas by Units Sold (millions), 2015
Figure 14: Medical Device Market, Spain, Revenue ($bn), 2009-2016
Figure 15: Medical Device Market, Spain, Revenue ($bn), 2017-2021
Figure 16: Medical Device Market, Spain, Revenue by Segment ($m), 2016
Figure 17: In Vitro Diagnostics Market, Spain, Revenue ($m), 2009-2016
Figure 18: In Vitro Diagnostics, Spain, Market Share of Major Players (%), 2014
Figure 19: Diabetes Care Device Market, Spain, Revenue ($m), 2009-2016
Figure 20: : Diabetes Care Device Market, Spain, Market Share of Major Players (%), 2015
Figure 21: Ophthalmic Device Market, Spain, Revenue ($m), 2009-2016
Figure 22: Ophthalmic Devices, Spain, Market Share of Major Players (%), 2015
Figure 23: Orthopedic Devices, Spain, Revenue ($m), 2009-2016
Figure 24: Orthopedic Devices, Spain, Market Share of Major Players (%), 2016
Figure 25: Hospital Supplies Market, Spain, Revenue ($m), 2009-2016
Figure 26: Hospital Supplies Market, Spain, Market Share of Major Players (%), 2014
Figure 27: Medical Device Market, Spain, Diagnostic Market, Revenue ($bn), 2009-2016
Figure 28: Medical Device Market, Spain, Diagnostic Market, Revenue ($bn), 2017-2021
Figure 29: Medical Device Market, Spain, Revenue of Major Players ($m), 2012
Figure 30: Healthcare Market, Spain, Drivers and Barriers, 2017
Figure 31: Market Access, Spain, Healthcare System, 2014
Figure 32: Healthcare System, Spain, Health Technology Assessment Process, 2014
Figure 33: Healthcare Expenditure, Spain, Out-of-Pocket Expenditure as Percentage of Total Expenditure (%), 2009-2016
Figure 34: Market Access, Spain, Healthcare Consumer Price Index Annual Change (%), 2009-2016
Figure 35: Market Access, Spain, Organizational Structure of AEMPS, 2016
Figure 36: Market Access, Spain, National Procedure, 2014
Figure 37: Market Access, EU, Centralized Procedure for Market Authorization, Pre-submission, 2016
Figure 38: Market Access, EU, Centralized Procedure, Market Authorization, Pre-opinion Phase, 2016
Figure 39: Market Access, EU, Centralized Procedure, Market Authorization, Post-opinion Phase, 2016
Figure 40: Market Access, EU, Decentralized Procedure, Market Authorization, 2016
Figure 41: Market Access, EU, Mutual Recognition Procedure, 2016
Figure 42: Market Access, EU, Conformity Assessment of Class I Medical Devices, 2016
Figure 43: Market Access, EU, Conformity Assessment of Class IIa Medical Devices, 2016
Figure 44: Market Access, EU, Conformity Assessment of Class IIb Medical Devices, 2016
Figure 45: Market Access, EU, Conformity Assessment of Class III Medical Devices, 2016
Figure 46: Economic Indicators, Spain, GDP per Capita ($), 2009-2016
Figure 47: Economic Indicators, Spain, GDP per Capita ($), 2017-2021
Figure 48: Economic Indicators, Spain, GDP Annual Growth (%), 2009-2016
Figure 49: Economic Indicators, Spain, GDP Annual Growth (%), 2017-2021
Figure 50: Economic Indicators, Spain, GNI per Capita ($), 2009-2016
Figure 51: Economic Indicators, Spain, Consumer Price Index, 2009-2016
Figure 52: Economic Indicators, Spain, Average Consumer Price Index, 2017-2021
Figure 53: Economic Indicators, Spain, Average Consumer Price Index, Annual Change (%), 2009-2016
Figure 54: Economic Indicators, Spain, Currency Exchange Rate (€/$), 2009-2016
Figure 55: Economic Indicators, Spain, Foreign Direct Investment ($bn), 2009-2016
Figure 56: Economic Indicators, Spain, Foreign Exchange Reserves ($bn), 2009-2016
Figure 57: Economic Indicators, Spain, Imports of Goods and Services ($bn), 2009-2016
Figure 58: Economic Indicators, Spain, Exports of Goods and Services ($bn), 2009-2016
Figure 59: Economic Indicators, Spain, Government Structural Balance ($bn), 2009-2016
Figure 60: Economic Indicators, Spain, Government Net Debt as Percentage of GDP (%), 2009-2016
Figure 61: Economic Indicators, Spain, Government Net Debt as Percentage of GDP (%), 2017-2021
Figure 62: Economic Indicators, Spain, Major Industries by Revenue ($bn), 2014
Figure 63: Demographics, Spain, Population (million), 2009-2016
Figure 64: Demographics, Spain, Population (million), 2017-2021
Figure 65: Demographics, Spain, Urban-Rural Population Share (%), 2009-2016
Figure 66: Demographics, Spain, Urban-Rural Population Share (%), 2017-2021
Figure 67: Demographics, Spain, Population Distribution by Age Group (%), 2009-2016
Figure 68: Demographics, Spain, Population Distribution by Age Group (%), 2017-2021
Figure 69: Demographics, Spain, Births (per 1,000 population), 2009-2016
Figure 70: Demographics, Spain, Mortality (per 1,000 population), 2009-2016
Figure 71: Demographics, Spain, Major Causes of Mortality , 2013
Figure 72: Demographics, Spain, Mortality Rate of Children Under Five (per 1,000 live births), 2009-2016
Figure 73: Demographics, Spain, Immunization Rate (%), 2009-2016
Figure 74: Demographics, Spain, Major Causes of Male Mortality 2013
Figure 75: Demographics, Spain, Major Causes of Female Mortality, 2013
Figure 76: Demographics, Spain, Gender Ratio (M/F), 2009-2016
Figure 77: Demographics, Spain, Life Expectancy at Birth (years), 2009-2016
Figure 78: Demographics, Spain, Students Enrolled at Different Levels in Non-university Courses (%), 2014-2015
Figure 79: Demographics, Spain, Students Enrolled at Different Levels in University Courses (%), 2013-2014
Figure 80: Demographics, Spain, Unemployment Rate (%), 2009-2016
Figure 81: Demographics, Spain, Distribution of Employment by Sector (%), 2015
Figure 82: Demographics, Spain, Number of Hospital Admissions and Diseases Diagnosed, 2015
Figure 83: Demographics, Spain, Major Diseases, Disability-Adjusted Life Years (000’), 2014
Figure 84: Healthcare Infrastructure, Spain, Hospitals, 2009-2016
Figure 85: Healthcare Infrastructure, Spain, Number of Hospitals by Type of Treatment, 2009-2016
Figure 86: Healthcare Infrastructure, Spain, Number of Hospitals by Sector, 2009-2016
Figure 87: Healthcare Infrastructure, Spain, Number of Hospital Beds by Sector, 2009-2016
Figure 88: Healthcare Infrastructure, Spain, Hospital Beds by Type of Treatment Provided, 2009-2016
Figure 89: Healthcare Infrastructure, Spain, Diagnostic Units (per 100,000 population), 2009-2016
Figure 90: Healthcare Infrastructure, Spain, Hospitals Beds (per 1,000 population), 2009-2016
Figure 91: Healthcare Infrastructure, Spain, Doctors (per 1,000 population), 2009-2016
Figure 92: Healthcare Infrastructure, Spain, PM2.5 (µg per m³), 2009-2016
Figure 93: Healthcare Infrastructure, Spain, CO2 Emissions (metric tons per capita), 2009-2016
Figure 94: Healthcare Infrastructure, Spain, Nurses, 2009-2016
Figure 95: Healthcare Infrastructure, Spain, Pharmacists, 2009-2016
Figure 96: Healthcare Infrastructure, Spain, Dentists, 2009-2016
Figure 97: Healthcare Infrastructure, Spain, Qualified Midwives, 2009-2016
Figure 98: Healthcare Infrastructure, Spain, Healthcare Expenditure as Percentage of GDP (%), 2009-2016
Figure 99: Healthcare Infrastructure, Spain, Public-Private Share of Expenditure (%), 2009-2016
Figure 100: Healthcare Infrastructure, Spain, Major Components of Healthcare Expenditure (%), 2015
Figure 101: Healthcare Infrastructure, Spain, R&D Expenditure by Field (%), 2013
Figure 102: Healthcare Market, Spain, Opportunities and Challenges,
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Baxter
  • GSK
  • Johnson & Johnson
  • Paul Hartmann
  • MORE
Austerity measures implemented by the Spanish government have negated the effect of key drivers behind the country’s pharmaceutical market, resulting in a contracting market between 2008 and 2020, says research and consulting firm The authors.

However, the company’s latest report* states that factors, such as an aging population and free healthcare service, will help drive an overall expansion of the country’s healthcare market over the next six years.

According to The authors, Spain’s medical devices space was worth approximately $7.1 billion in 2008 and increased to around $8.5 billion in 2013, at a Compound Annual Growth Rate (CAGR) of 3.4%. It is expected to reach $12 billion by 2020, representing a CAGR of 5%.

The in vitro diagnostics and diabetic care device segments were the largest contributors to Spain’s medical device market in 2013. Other major segments included orthopedic, cardiovascular and ophthalmic devices.

Joshua Owide, The authors’s Director of Healthcare Industry Dynamics, says: “Spain’s medical devices sector is benefiting significantly from the increase in electronic health services and a strong MedTech industry. However, new drug pricing policies and the promotion of generics as a cost-containment tool are severely limiting the country’s pharmaceutical market growth.

“The government’s new policies, introduced in 2011 and 2012, require drug manufacturers to price their products lower than the reference price, and it is now mandatory for pharmacists to dispense the cheapest available drugs to patients, further impacting pharmaceutical market value.”

The authors states that due to these strict regulations to contain costs by 2020, the Association Européenne des Spécialités Pharmaceutiques Grand Public (AESGP) reported a decline in Spain’s pharmaceutical market revenues, from $29 billion in 2008 to $24 billion in 2013, at a negative CAGR of 3.7%.

The market’s value is expected to decrease even further to $22.6 billion by the end of the forecast period, representing a negative CAGR of 0.9%.

*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Spain

This report provides information on the healthcare, regulatory, and reimbursement landscape in Spain. It includes an overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers, as well as an evaluation of the opportunities for and challenges to growth.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by The authors’s team of industry experts.
Note: Product cover images may vary from those shown
5 of 6
  • GSK
  • Baxter
  • Johnson & Johnson
  • Svenska Cellulosa Aktiebolaget
  • Paul Hartmann
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll